Pharma's "Vision" for the Future or Three Blind Mice?

Daniel R. Hoffman, Ph.D.

Last month the pharma columnist at Forbes, Matthew Herper, wrote that after "talking to executives around the drug industry," most are pursuing one of the following three alternative scenarios: The blockbuster model, the expanded orphan strategy and the access model. Here, I offer up some insight into each of these "visions" of the future:

1) The blockbuster model. Three or four years after it became conventional wisdom in pharma that the blockbuster model was dead, Herper now claims that "many executives still hold to basically this model." He's probably correct and, as much as anything, that fact reveals the dearth of innovative thinking and the CYA behavior in pharma's C-suites.

Basically any intent on pharma's part to persist with...

Bookmark and Share

Notice: We utilize cookies and other web technologies on our site. For more information regarding our use of web technologies, please review our Privacy Policy.